Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ: ASPI) announced that its wholly owned subsidiary Quantum Leap Energy (QLE) has signed a research agreement with the Texas A&M Engineering Experiment Station (TEES) to support commercialization of high-purity uranium hexafluoride (UF6), a key feedstock for nuclear fuel enrichment. The collaboration will collect fundamental physicochemical data on converting yellowcake uranium (U3O8) into UF6, with the aim of improving production efficiency, reducing costs, and enhancing scalability. According to the company, the work is expected to inform QLE’s process design, modeling, and scale-up activities, reinforce its uranium conversion technology efforts, and contribute to a more resilient U.S. nuclear fuel supply chain and a stronger nuclear ecosystem in Texas.
ASP Isotopes (NASDAQ:ASPI) and ENDRA Life Sciences (NASDAQ:NDRA) will participate in a RedChip investor webinar on July 21, 2026, at 4:15 p.m. ET, featuring Noble Africa, a wholly owned ASPI subsidiary and holding company for Renergen’s Virginia Gas Project.
The webinar will discuss Noble Africa’s proposed merger with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company under the ticker “NOBA”. CEO Paul Mann will outline the Virginia Gas Project helium and LNG platform, its planned Phase 1 production ramp in 2026, Phase 2 expansion plans, key operational and financing milestones, and how a proposed Nasdaq listing is expected to support Noble Africa’s long-term growth strategy. A live Q&A session will follow.
ASP Isotopes (NASDAQ: ASPI) and its wholly owned subsidiary Quantum Leap Energy (QLE) entered into privately negotiated exchange agreements with certain holders of QLE’s convertible promissory notes. Holders agreed to exchange approximately $109.2 million in aggregate principal plus accrued interest for about 23.2 million ASPI common shares, representing roughly 17.8% of ASPI’s outstanding common stock.
The transactions are intended to cut QLE’s outstanding convertible notes by about 50%, reducing principal from $219.8 million to $110.7 million, simplify QLE’s capital structure as it pursues a separate U.S. listing, and support ASPI’s position for a potential future distribution of QLE equity. Closing is expected on July 16, 2026, subject to customary conditions.
ASP Isotopes (NASDAQ:ASPI) announced a Proposed Merger of its wholly owned subsidiary Noble Africa with a subsidiary of ENDRA Life Sciences (NASDAQ:NDRA). The surviving company plans to be renamed Noble Africa and apply to list on Nasdaq under the ticker NOBA.
In connection with the Proposed Transactions, Noble Africa has secured commitments for a concurrent private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes and about $30 million from other investors, to support development of Renergen’s Virginia Gas Project.
ASP Isotopes (NASDAQ: ASPI)/b) announced that Tetra4, developer of the Virginia Gas Project in South Africa, signed its first five-year take-or-pay contract to supply contained helium to an Asian industrial gases company at an initial base price above
ASP Isotopes (NASDAQ: ASPI) restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, which have operated for over three weeks at target enrichment levels.
Engineering enhancements to non-core components are planned for remaining stages, supporting three U.S. contracts and expected initial commercial shipments in Q3 2026.
ASP Isotopes (NASDAQ: ASPI) announced that subsidiary Quantum Leap Energy signed a non-binding MOU with a European advanced nuclear reactor developer to assess long-term HALEU fuel supply. The framework covers uranium feedstock supply, conversion, enrichment above 10% U-235, potential deconversion, and deliveries potentially starting in 2028, with the MOU running through 2030.
Quantum Leap Energy (ASPI) appointed Dr. Peter S. Fiske to its Strategic Advisory Board on May 6, 2026. Dr. Fiske brings experience in technology commercialization, advanced materials, and government partnerships, including leadership of the DOE-backed National Alliance for Water Innovation.
The appointment follows QLE's recent SAB formation, CTO Nate Salpeter hire, and a strategic collaboration with the University of Bristol on a lithium laser research facility.
Skyline Builders Group Holding Ltd and Cove Kaz Capital Group LLC (ASPI) announced a transaction to combine into Kaz Resources Inc. (expected Nasdaq: KAZR) to develop Kazakhstan critical-minerals projects.
Key facts: acquisition closed April 29, 2026; largest undeveloped tungsten resource of 1.4 million tonnes WO3; expected production 12,000 mtpa; EXIM and DFC issued LOIs totaling $1.6 billion; estimated development cost $1.1 billion.
ASP Isotopes (NASDAQ: ASPI) provided a business update on April 13, 2026 outlining near-term commercial milestones, operational progress, and financials. The company expects first commercial shipments across Silicon-28, Carbon-14, and Yb-176 in 2026, and Helium Phase 1 nameplate capacity in Q3 2026. Cash and equivalents were $333 million as of December 31, 2025, product revenue was $5.7 million in 2025, and a long-term EBITDA target of greater than $300 million in 2031 was reiterated.